Edition:
United States

Threshold Pharmaceuticals Inc (THLD.OQ)

THLD.OQ on NASDAQ Stock Exchange Capital Market

0.48USD
25 Jul 2017
Change (% chg)

-- (--)
Prev Close
$0.48
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
151,760
52-wk High
$1.48
52-wk Low
$0.35

THLD.OQ

Chart for THLD.OQ

About

Threshold Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. It is developing two therapeutic product candidates based on hypoxia-activat... (more)

Overall

Beta: 3.27
Market Cap(Mil.): $35.07
Shares Outstanding(Mil.): 71.59
Dividend: --
Yield (%): --

Financials

  THLD.OQ Industry Sector
P/E (TTM): -- 214.05 15.73
EPS (TTM): -0.30 -- --
ROI: -80.11 -7.97 -8.37
ROE: -86.65 -9.29 -7.93

BRIEF-Threshold Pharma says first patient dosed in clinical trial of evofosfamide, ipilimumab

* Threshold Pharmaceuticals announces first patient dosed in immunotherapy clinical trial of evofosfamide and ipilimumab

Jun 13 2017

BRIEF-OBI Pharma buys TH-3424 from Threshold Pharmaceuticals

* OBI Pharma announces acquisition of TH-3424 from Threshold Pharmaceuticals

Jun 01 2017

BRIEF-Threshold Pharmaceuticals files for non-timely 10-Q

* Threshold Pharmaceuticals says due to connectivity issues with Edgar server, co was unable to file form 10-Q for period ended March 31, 2017 Source text for Eikon: (http://bit.ly/2qtGHCc) Further company coverage:

May 16 2017

BRIEF-Threshold Pharmaceuticals reports Q1 loss per share of $0.07

* Threshold Pharmaceuticals reports first quarter financial results

May 15 2017

BRIEF-Threshold Pharmaceuticals posts Q4 loss of $3.7 mln

* Threshold pharmaceuticals reports fourth quarter and full year 2016 financial results

Mar 27 2017

BRIEF-Threshold Pharmaceuticals and Molecular Templates agree to combine

* Threshold Pharmaceuticals and Molecular Templates agree to combine

Mar 17 2017

BRIEF-First Eagle Investment Management LLC reports 9.91 pct passive stake in Threshold Pharmaceuticals

* First Eagle Investment Management LLC reports a 9.91 percent passive stake in Threshold Pharmaceuticals Inc as on December 31, 2016 - SEC filing Source text (http://bit.ly/2kkln0x) Further company coverage:

Feb 06 2017

Competitors

Earnings vs. Estimates